Kentucky Retirement Systems Insurance Trust Fund Takes Position in Hologic, Inc. (NASDAQ:HOLX)

Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 6,461 shares of the medical equipment provider's stock, valued at approximately $399,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Smartleaf Asset Management LLC grew its stake in Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Dark Forest Capital Management LP grew its stake in Hologic by 7.9% in the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock valued at $220,000 after purchasing an additional 223 shares in the last quarter. Baker Avenue Asset Management LP grew its stake in Hologic by 0.5% in the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock valued at $3,031,000 after purchasing an additional 225 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its stake in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Buying and Selling

In other news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the purchase, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.88% of the stock is owned by insiders.

Hologic Stock Performance

Shares of NASDAQ HOLX traded down $0.10 during trading hours on Friday, hitting $65.01. 3,320,131 shares of the company's stock were exchanged, compared to its average volume of 2,369,901. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The stock has a market capitalization of $14.49 billion, a price-to-earnings ratio of 27.43, a PEG ratio of 2.38 and a beta of 0.55. The company's 50-day moving average price is $60.00 and its 200-day moving average price is $63.90.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the previous year, the firm earned $1.03 EPS. The firm's revenue was down 1.2% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on HOLX shares. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Evercore ISI lowered their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Raymond James Financial restated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Morgan Stanley reduced their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $77.42.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.